{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:41:56Z","timestamp":1783705316800,"version":"3.55.0"},"reference-count":31,"publisher":"Baishideng Publishing Group Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Clin Cases"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n          <jats:p>Yangxue Qingnao Granules (YXQN) is a Chinese patent medicine that has been commonly used in the clinical treatment of migraine.<\/jats:p>\n          <jats:p>AIM<\/jats:p>\n          <jats:p>To assess the efficacy and safety of YXQN alone for the treatment of migraine.<\/jats:p>\n          <jats:p>METHODS<\/jats:p>\n          <jats:p>We searched 10 databases to identify relevant randomized controlled trials (RCTs) published before September 2022. Two review authors independently searched and screened the literature, extracted the data, and assessed the methodological quality of the studies using criteria from ROB 2.0, and analyzed the data using Review Manager 5.4 software.<\/jats:p>\n          <jats:p>RESULTS<\/jats:p>\n          <jats:p>A total of 12 RCTs including 767 participants with migraine met the selection criteria. We divided these studies into comparisons of YXQN with placebo, routine treatment drugs, and other Chinese patent medicines. The meta-analysis showed the following: (1) Efficacy: The YXQN group outperformed the placebo group [relative risk (RR) = 0.29, 95% confidence interval (95%CI): 0.15\u20130.43, P  &lt; 0.00001], routine treatment group (RR = 0.18, 95%CI: 0.09\u20130.27, P  &lt; 0.0001), and Chinese patent medicine group (RR = 0.27, 95%CI: 0.13\u20130.41, P  &lt; 0.001); (2) frequency of headache: There was a significant difference between YXQN vs  placebo [mean difference (MD) = -1.25,  95%CI: -1.60 to -0.90, P  &lt; 0.00001], routine treatment drugs (MD = -0.85, 95%CI: -1.15 to -0.56, P  &lt; 0.00001), and Chinese patent medicine (MD = -0.91, 95%CI: -1.35 to -0.46, P  &lt; 0.0001); (3) headache duration: We found great heterogeneity between studies, with no differences between YXQN and placebo (MD = -0.61, 95%CI: -1.53 to -0.31, P  = 0.19) and routine treatment drugs (MD = -0.22, 95%CI: -0.89 to 0.46, P  &lt; 0.53). YXQN was more effective than other Chinese patent medicines in reducing headache duration (MD = -1.24, 95%CI: -1.70 to -0.77, P  &lt; 0.00001); and (4) headache severity: There was no significant difference between YXQN vs  placebo (MD = -1.67, 95%CI: -3.52 to 0.19, P  = 0.08), routine treatment drugs (MD = -0.53, 95%CI: -2.02 to 0.96, P  = 0.68), and other Chinese patent medicines (MD = -0.49, 95%CI: -2.83 to 1.85, P  = 0.68). Mild gastrointestinal adverse reactions were reported in three cases.<\/jats:p>\n          <jats:p>CONCLUSION<\/jats:p>\n          <jats:p>This study revealed that YXQN is effective and safe for treatment of migraine.<\/jats:p>","DOI":"10.12998\/wjcc.v12.i2.335","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T10:10:01Z","timestamp":1704881401000},"page":"335-345","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of Yangxue Qingnao Granules in treatment of migraine: A systematic review and meta-analysis"],"prefix":"10.12998","volume":"12","author":[{"given":"Bo","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ning","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-Qin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Gang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31678-6"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2018.00201"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0373-15.2015"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/head.12505_2"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.041007646.x"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2015"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.02.013"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32154-2"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.93840"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4088\/pcc.v07n0201"},{"key":"B13","unstructured":"Assarzadegan F, Sistanizad M. Tolerability and Efficacy of Memantine as Add on Therapy in Patients with Migraine. Iran J Pharm Res 2017; 16: 791-797"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.19540\/j.cnki.cjcmm.20200729.501"},{"key":"B15","unstructured":"Chen FC, Mu YQ, Peng L, Li P, Qian N, Feng LB. Meta analysis of Yangxue Qingnao Granule combined with Flunarizine hydrochloride in the treatment of migraine. Xiandai Zhongxiyi Jiehe Zazhi 2013; 22: 146-148"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/0333102411417901"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"B18","unstructured":"Li ZW. A Comparative Study on the Treatment of Migraine with Yangxue Qingnao Granules. Chongqing Yixue 2003; 628-629"},{"key":"B19","unstructured":"Li Z, Li C, Liu K. Yangxue Qingnao Granules for the Treatment of 79 Cases of Migraine. Shiyong Zhongyi Neike Zazhi 2003; 230-231"},{"key":"B20","unstructured":"He F. A Clinical Study of Yangxue Qingnao Granules in Treatment of Migraine. Luzhou Yixueyuan Xuebao 2005; 05: 39-41"},{"key":"B21","unstructured":"Bai H. Yangxue Qingnao Granules for Treating 28 Cases of Migraine. Zhongguo Xiandai Yaowu Yingyong 2011; 5: 67-68"},{"key":"B22","unstructured":"Zhang Z, Kuang S. Clinical Study of Yangxue Qingnao Granule in the Treatment of Migraine. Xiandai Zhenduan Yu Zhiliao 2015; 26: 766-768"},{"key":"B24","unstructured":"Xie Z, Peng H. Clinical Study of Yangxue Qingnao Granule in the Prevention and Treatment of Migraine. Yatai Chuantong Yiyao 2017; 13: 127-128"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.19738\/j.cnki.psy.2020.02.169"},{"key":"B26","unstructured":"Li Y, Liu N. Comparative Study on the Treatment of Migraine with Yangxue Qingnao Granules. Shiyong Yiji Zazhi 2012; 19: 1309-1310"},{"key":"B27","unstructured":"Niu Z, Hou Y, Ren X. Study on the Effect of Yangxue Qingnao Granules on Migraine Patients. Zhongxiyi Jiehe Xinnao Xueguan Zazhi 2003; 06: 327-329"},{"key":"B28","unstructured":"Wang L. Clinical Discussion on the Prevention and Treatment of Yangxue Qingnao Granules. Jiankang Zhiyou 2021; 000: 278"},{"key":"B29","unstructured":"Jiang G. Observation of the Efficacy of Yangxue Qingnao Granules to the Treatment of Migraines. Zhongyi Linchuang Yanjiu 2019; 11: 136-138"},{"key":"B30","unstructured":"Zhao P, Niu Z, Liu P. Effect of Yangxue Qingnao Granule on degranulation of Dura mater Mast cell in migraine rats. Zhongxiyi Jiehe Xinnao Xueguanbing Zazhi 2013; 11: 1364-1366"},{"key":"B31","unstructured":"Lei X, Zhao P, Niu Z. An experimental research on the expression of c \u2043 Fos protein in trigeminal nucleus caudalis of migraine rat model induced by nitroglycerin after the intervention of Yangxueqingnao granules. Zhongguo Xiandai Shenjing Jibing Zazhi 2014; 14: 708-716"},{"key":"B32","unstructured":"Li Y. Effect of Yangxue Qingnao Granule on headache symptoms and Hemorheology in migraine patients. Linchuang Yiyao Wenxian Dianzi Zazhi 2016; 3: 11617-11618"}],"container-title":["World Journal of Clinical Cases"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v12\/i2\/335.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v12\/i2\/335.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T10:11:24Z","timestamp":1704881484000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/2307-8960\/full\/v12\/i2\/335.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":31,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.12998\/wjcc.v12.i2.335","relation":{},"ISSN":["2307-8960"],"issn-type":[{"value":"2307-8960","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,16]]}}}